Logo

ASBPW

Aspire Biopharma Holdings, Inc.

ASBPW

Aspire Biopharma Holdings, Inc. • NASDAQ
$0.02 ▼ -24.67% (-0.01)
Market Cap $1.12 M
52w High $0.04
52w Low $0.02
Dividend Yield 0%
P/E 0
Volume 5.15K
Outstanding Shares 49.53M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.941K ▲ $1.146M ▲ $-1.85M ▲ -95.337K% ▼ $-0.037 ▲ $0 ▲
Q2-2025 $0 $799.89K ▼ $-1.981M ▲ 0% $-0.04 ▲ $-1.453M ▲
Q1-2025 $0 $15.556M ▲ $-15.941M ▼ 0% $-0.42 ▲ $-15.651M ▼
Q4-2024 $0 $2.518M ▲ $-11.966M ▼ 0% $-1.15 ▼ $-11.075M ▼
Q3-2024 $0 $242.616K $-244K 0% $-0.069 $-243K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.948M ▲ $2.403M ▲ $13.87M ▲ $-11.467M ▼
Q2-2025 $206.233K ▼ $989.422K ▼ $10.606M ▲ $-9.617M ▼
Q1-2025 $1.347M ▲ $1.966M ▲ $8.918M ▲ $-6.953M ▼
Q4-2024 $3.633K ▼ $147.989K ▼ $1.688M ▲ $-1.54M ▼
Q3-2024 $16.541K $184.041K $985.629K $-801.588K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.85M ▲ $-1.104M ▲ $0 $2.846M ▲ $1.742M ▲ $-1.104M ▲
Q2-2025 $-1.981M ▲ $-1.14M ▲ $0 $0 ▼ $-1.14M ▼ $-1.14M ▲
Q1-2025 $-15.941M ▼ $-1.752M ▼ $0 $3.094M ▲ $1.343M ▲ $-1.752M ▼
Q4-2024 $-738.5K ▼ $479.569K ▲ $0 ▼ $-492.477K ▼ $-12.908K ▼ $479.569K ▲
Q3-2024 $-243.629K $-533.798K $38.258K $492.477K $-3.063K $-495.54K

Five-Year Company Overview

Income Statement

Income Statement Aspire Biopharma is still a pre‑revenue biotech story. The company has essentially no product sales yet, so results are driven almost entirely by R&D and corporate costs rather than commercial activity. Recent figures show the business running at a loss, which is normal for such an early stage, but it does mean there is no underlying earnings base to lean on. Earnings per share have bounced around, which likely reflects one‑off SPAC and capital structure effects more than any change in the underlying business performance. Overall, the income statement tells a clear story: this is a development‑stage company burning money to build future products, not one generating steady profits today.

Balance Sheet

Balance Sheet The reported balance sheet data are minimal and not very informative, which suggests either limited public disclosure in this format or a very small current operating footprint. For an early‑stage biotech born from a SPAC, the real questions usually center on how much cash is available versus expected development spending and how much additional capital will be needed. With the snapshot here showing little detail on assets, cash, debt, or equity, it’s hard to assess financial cushion or leverage from these numbers alone. Investors would typically look beyond this summary to more detailed filings to understand runway, obligations, and dilution risk.

Cash Flow

Cash Flow The cash flow figures shown are essentially flat, which likely reflects either very low recorded spending in this summary or incomplete data, rather than a genuinely cash‑neutral operation. In practice, a company at this stage usually has negative operating cash flow as it pays for research, trials, and corporate overhead, funded by past or new capital raises. Free cash flow is therefore almost certainly negative in economic terms, even if this specific table doesn’t fully show it. The key takeaway: the business is not self‑funding and will depend on external financing until products reach the market, if they do.

Competitive Edge

Competitive Edge Aspire operates in a highly competitive slice of biotech: drug delivery and reformulation rather than inventing entirely new molecules. Its niche is sublingual delivery—getting medicines absorbed quickly under the tongue to act faster and sometimes more efficiently than standard pills. That idea is attractive and has clear medical use cases, and Aspire is trying to protect it with patents around its formulations and micelle‑based technology. However, it faces well‑established competitors that already market fast‑acting films and orally disintegrating tablets. Aspire’s edge will need to come from convincingly faster onset, better absorption, or better patient experience, backed by strong clinical data. Until then, its competitive position is promising in concept but unproven in practice, and it competes against larger, better‑funded players.

Innovation and R&D

Innovation and R&D Innovation is where Aspire stands out most. The company’s platform aims to repurpose known drugs into sublingual versions that act more quickly and may be easier on patients. Its lead candidate, a sublingual aspirin (Instaprin), targets rapid treatment in heart‑attack‑like situations, where seconds and minutes matter. Early data suggest it may get active drug into the bloodstream faster than chewed tablets. Beyond that, Aspire is exploring sublingual versions of erectile‑dysfunction drugs, semaglutide for diabetes and weight management, and other medicines and supplements. This strategy of reformulating existing drugs can shorten development timelines compared with brand‑new compounds, but it still requires solid clinical results and regulatory approvals. The micelle‑based technology mentioned could be a differentiator if it truly improves solubility and absorption, but public evidence is still limited, so the true strength of this moat is not yet clear.

Summary

Aspire Biopharma is an early‑stage, platform‑driven biotech centered on faster, under‑the‑tongue delivery of familiar drugs. Financially, it is pre‑revenue and loss‑making, with limited detail here on its cash and balance sheet strength, which underscores the typical risks of a young biotech that depends on external funding. Strategically, the company has a focused and potentially useful technology, several pipeline programs anchored by Instaprin, and a development path that leverages known drugs to try to reduce risk and timelines. At the same time, it operates in a crowded field against larger, established drug‑delivery specialists and still must prove that its approach delivers clear clinical and commercial advantages. Overall, the story is driven far more by future scientific, regulatory, and financing milestones than by current financial performance.